LBX(SH:603883)2020-04-27 16:00Financial Performance - Net profit attributable to shareholders increased by 23.01% to CNY 196,115,130 year-on-year[4] - Operating revenue rose by 20.34% to CNY 3,282,152,609 compared to the same period last year[4] - Basic earnings per share increased by 23.21% to CNY 0.69 per share[4] - Total revenue for the company reached CNY 3,282,152,609, representing a year-over-year increase of 20.34%[15] - The net profit for Q1 2020 reached CNY 69,079,443, a significant decrease of 85.4% from CNY 473,656,400 in Q1 2019[32] - The total profit for Q1 2020 was CNY 91,622,652, down from CNY 492,868,868 in Q1 2019, a decline of 81.5%[32] Assets and Liabilities - Total assets increased by 8.11% to CNY 10,728,921,907 compared to the end of the previous year[4] - The company reported a total current liability of CNY 5,880,464,889, an increase from CNY 5,347,946,036 at the end of 2019[22] - The company's total equity increased to ¥4,114,994,655 from ¥3,874,731,741, representing a rise of 6.2%[23] - The total liabilities increased to ¥4,959,705,309 from ¥4,406,277,682, reflecting a growth of 12.5%[27] Cash Flow - Net cash flow from operating activities increased by 1.86% to CNY 201,335,909 year-to-date[4] - The net cash flow from operating activities for Q1 2020 was CNY 201,335,909, a slight increase from CNY 197,650,612 in Q1 2019[35] - Cash inflow from operating activities totaled CNY 3,877,341,120 in Q1 2020, compared to CNY 3,030,198,716 in Q1 2019, representing a growth of approximately 28.1%[34] - The net cash flow from investing activities was negative at CNY (522,747,958) in Q1 2020, compared to CNY (257,428,673) in Q1 2019, indicating increased investment expenditures[35] - Cash inflow from financing activities reached CNY 682,283,719 in Q1 2020, significantly higher than CNY 159,268,103 in Q1 2019, reflecting a growth of approximately 328.5%[35] Shareholder Information - The total number of shareholders reached 9,388 at the end of the reporting period[7] - The largest shareholder, Laobai Medicine Group Co., Ltd., holds 34.61% of the shares[7] Operational Metrics - The number of stores increased to 5,438, including 4,115 direct-operated stores and 1,323 franchised stores, with 208 new self-built stores added during the period[12] - The company operates a total of 5,438 stores, including 4,115 direct-operated stores and 1,323 franchised stores, with a net addition of 208 self-built stores during the reporting period[16] Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in this report[6] - The company plans to continue expanding its market presence and enhancing its product offerings in the upcoming quarters[16] - The company launched a new micro-business platform "Kangle Youxuan," which attracted 420,000 members and 9.2 million visitors by the end of the reporting period[12] Government Support and Social Responsibility - The company received government subsidies amounting to CNY 36,977,716 during the reporting period[5] - The company donated over 2.95 million CNY worth of medical supplies during the pandemic, enhancing its social responsibility image[12] Research and Development - The company has invested in new product development, with R&D expenses recorded at ¥8,233,256 for the quarter[26] - The company's research and development expenses for Q1 2020 were CNY 150,000, compared to zero in the same period last year, indicating a new investment in R&D[31] Financial Ratios - The weighted average return on equity increased by 0.41 percentage points to 5.47%[4] - The gross margin for the overall business was 33.08%, a decrease of 1.12% compared to the previous year[15] - The gross margin for the retail pharmacy segment was 36.01%, with a slight decrease of 0.90% compared to the previous year[14] - The gross margin for the Chinese herbal medicine segment was 51.96%, showing a slight increase of 0.29% year-over-year[15]